JP2008189679A5 - - Google Patents

Download PDF

Info

Publication number
JP2008189679A5
JP2008189679A5 JP2008066772A JP2008066772A JP2008189679A5 JP 2008189679 A5 JP2008189679 A5 JP 2008189679A5 JP 2008066772 A JP2008066772 A JP 2008066772A JP 2008066772 A JP2008066772 A JP 2008066772A JP 2008189679 A5 JP2008189679 A5 JP 2008189679A5
Authority
JP
Japan
Prior art keywords
mitiglinide
hydrate
acceptable salt
pharmacologically acceptable
voglibose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008066772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008189679A (ja
JP5117230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2008066772A priority Critical patent/JP5117230B2/ja
Priority claimed from JP2008066772A external-priority patent/JP5117230B2/ja
Publication of JP2008189679A publication Critical patent/JP2008189679A/ja
Publication of JP2008189679A5 publication Critical patent/JP2008189679A5/ja
Application granted granted Critical
Publication of JP5117230B2 publication Critical patent/JP5117230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008066772A 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬 Active JP5117230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008066772A JP5117230B2 (ja) 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005121862 2005-04-20
JP2005121862 2005-04-20
JP2005166314 2005-06-07
JP2005166314 2005-06-07
JP2008066772A JP5117230B2 (ja) 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007514602A Division JP4230524B2 (ja) 2005-04-20 2006-04-18 2型糖尿病治療用の併用医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000738A Division JP2012092140A (ja) 2005-04-20 2012-01-05 2型糖尿病治療用の併用医薬

Publications (3)

Publication Number Publication Date
JP2008189679A JP2008189679A (ja) 2008-08-21
JP2008189679A5 true JP2008189679A5 (enExample) 2012-03-15
JP5117230B2 JP5117230B2 (ja) 2013-01-16

Family

ID=37214736

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007514602A Active JP4230524B2 (ja) 2005-04-20 2006-04-18 2型糖尿病治療用の併用医薬
JP2008066772A Active JP5117230B2 (ja) 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬
JP2012000738A Pending JP2012092140A (ja) 2005-04-20 2012-01-05 2型糖尿病治療用の併用医薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007514602A Active JP4230524B2 (ja) 2005-04-20 2006-04-18 2型糖尿病治療用の併用医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000738A Pending JP2012092140A (ja) 2005-04-20 2012-01-05 2型糖尿病治療用の併用医薬

Country Status (7)

Country Link
US (1) US7888382B2 (enExample)
EP (1) EP1872781A4 (enExample)
JP (3) JP4230524B2 (enExample)
KR (1) KR101380813B1 (enExample)
CN (1) CN101198326B (enExample)
CA (1) CA2605302A1 (enExample)
WO (1) WO2006115115A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605302A1 (en) * 2005-04-20 2006-11-02 Kissei Pharmaceutical Co., Ltd. Combined pharmaceutical preparation for treatment of type 2 diabetes
CN105296620B (zh) 2015-10-26 2019-01-15 上海市内分泌代谢病研究所 肠道宏基因组特征作为2型糖尿病阿卡波糖疗效筛选标志
JP7680822B2 (ja) * 2017-08-08 2025-05-21 日本ケミファ株式会社 糖尿病治療剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040490A1 (en) * 2000-02-24 2003-02-27 Yasuo Sugiyama Drugs containing combined active ingredients
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
WO2004002473A1 (ja) 2002-06-28 2004-01-08 Kissei Pharmaceutical Co., Ltd. 血糖コントロール用医薬組成物
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
AU2004261660A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
WO2005082414A2 (en) * 2004-03-02 2005-09-09 Astellas Pharma Inc. Concomitant drugs of a sulfonamide and another therapeutic agent
CA2605302A1 (en) * 2005-04-20 2006-11-02 Kissei Pharmaceutical Co., Ltd. Combined pharmaceutical preparation for treatment of type 2 diabetes
WO2007033292A2 (en) 2005-09-14 2007-03-22 Elixir Pharmaceuticals, Inc. Combination therapy for controlled carbohydrate digestion

Similar Documents

Publication Publication Date Title
JP2014518860A5 (enExample)
JP2012512907A5 (enExample)
FI3716979T3 (fi) 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi
JP2006348039A5 (enExample)
WO2006105501A3 (en) Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
JP2010529118A5 (enExample)
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
NO20084321L (no) Triazolderivat eller salt derav
JP2010535252A5 (enExample)
JP2011500690A5 (enExample)
Grade et al. Standard perioperative management in gastrointestinal surgery
JP2012517449A5 (enExample)
JP2019089796A5 (enExample)
JP2018509419A5 (enExample)
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
JP2018503644A5 (enExample)
MX2009011900A (es) Curacion de herida diabetica.
WO2004062557A3 (de) Pharmazeutische kombination aus telmisartan und atorvastatinph zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten
JP2008189679A5 (enExample)
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
JP2009516719A5 (enExample)
JP2008266291A5 (enExample)
JP2013507383A5 (enExample)
UA108980C2 (en) APPLICATION OF DONEDARONE FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS